Medpace (NASDAQ:MEDP) CEO August Troendle Sells 5,534 Shares

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August Troendle sold 5,534 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $601.53, for a total value of $3,328,867.02. Following the completion of the transaction, the chief executive officer directly owned 633,412 shares in the company, valued at $381,016,320.36. The trade was a 0.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Medpace Trading Down 1.4%

NASDAQ MEDP traded down $8.52 during trading hours on Wednesday, reaching $596.98. 310,338 shares of the company’s stock were exchanged, compared to its average volume of 355,204. The firm has a fifty day moving average of $528.36 and a 200-day moving average of $491.85. Medpace Holdings, Inc. has a one year low of $373.00 and a one year high of $677.90. The stock has a market cap of $16.66 billion, a PE ratio of 34.99, a price-to-earnings-growth ratio of 2.69 and a beta of 1.15.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.98 by $0.27. The firm had revenue of $707.33 million during the quarter, compared to the consensus estimate of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The business’s revenue for the quarter was up 17.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, research analysts forecast that Medpace Holdings, Inc. will post 17.54 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on MEDP. Wall Street Zen cut Medpace from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. BMO Capital Markets upped their target price on shares of Medpace from $400.00 to $600.00 and gave the stock a “market perform” rating in a research report on Friday, July 24th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and set a $535.00 price target on shares of Medpace in a research note on Thursday, July 23rd. Royal Bank Of Canada raised their price target on shares of Medpace from $484.00 to $692.00 and gave the company an “outperform” rating in a report on Friday, July 24th. Finally, Truist Financial boosted their price objective on shares of Medpace from $462.00 to $609.00 and gave the stock a “hold” rating in a research report on Friday, July 24th. Two analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the company. According to data from MarketBeat.com, Medpace has an average rating of “Hold” and an average target price of $584.18.

Hedge Funds Weigh In On Medpace

Hedge funds and other institutional investors have recently bought and sold shares of the business. California State Teachers Retirement System grew its holdings in shares of Medpace by 22.1% in the 1st quarter. California State Teachers Retirement System now owns 26,042 shares of the company’s stock valued at $12,505,000 after acquiring an additional 4,719 shares in the last quarter. Cerity Partners LLC raised its holdings in Medpace by 41.0% during the fourth quarter. Cerity Partners LLC now owns 80,973 shares of the company’s stock worth $45,478,000 after acquiring an additional 23,530 shares in the last quarter. Northwestern Mutual Wealth Management Co. raised its holdings in Medpace by 24,930.4% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 101,373 shares of the company’s stock worth $56,936,000 after acquiring an additional 100,968 shares in the last quarter. Mitchell Capital Management Co. acquired a new position in Medpace during the fourth quarter valued at approximately $3,383,000. Finally, M&T Bank Corp boosted its position in Medpace by 1,596.0% during the fourth quarter. M&T Bank Corp now owns 14,128 shares of the company’s stock valued at $7,935,000 after purchasing an additional 13,295 shares during the last quarter. 77.98% of the stock is owned by institutional investors.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.